Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 3Recurrence 1Rectal Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myeloid, Acute 1Leukemia, Erythroblastic, Acute 1Hodgkin Disease 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × Salvage Therapy × Clear all
NCT06143605 2023-11-22

Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors

Sun Yat-sen University

Completed
527 enrolled
EndocrineGastrointestinalNET

Rectal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡